Celltrion USA Launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar

 Celltrion USA today announced the launch of Yuflyma^® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira^® (adalimumab) biosimilar, providing an alternative option for patients.

Yuflyma is indicated for the treatment of eight conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.¹

First approved by the Food and Drug Administration on May 23, 2023, Yuflyma became commercially available among key distributors across the U.S. on July 2^nd. Yuflyma is listed at $6,576.50 per month. Yuflyma is available in two device types — auto-injector and pre-filled syringe options.

More than 80% of patients treated with Humira in the U.S. rely on a high-concentration and citrate-free formulation.² Yuflyma is a citrate-free formulation that is highly concentrated at 100mg/mL. It also maintains stability at 25℃ (77°F) for 30 days to provide longer shelf life than Humira and is administered via a latex-free device.¹

^{https://www.biospace.com/article/releases/celltrion-usa-launches-yuflyma-adalimumab-aaty-a-humira-adalimumab-biosimilar-in-the-united-states/}